Review on hepatobiliary disorders and complications of ulcerative colitis
Keywords:
inflammatory bowel diseases, ulcerative colitis, hepatobiliary disorders, hepatobiliary complicationsAbstract
Inflammatory bowel diseases (IBD) are a group of chronic relapsing diseases of an autoimmune nature that affect various parts of the gastrointestinal tract. According to the European Organization for Research on Crohn's Disease (CD) and Ulcerative Colitis (UC), about 2.2 million people in Europe (and 5 million worldwide) suffer from these diseases. In recent years, there has been a tendency towards an increase in the number of severe, treatment-resistant forms of UC, complications and surgical interventions leading to disability in patients of young, working age, which determines medical -social relevance of the problem of these diseases. In more than a third of patients with UC, in addition to intestinal symptoms, extraintestinal manifestations are observed, which sometimes appear long before the manifestation of the classic clinical picture of UC, which significantly complicates and prolongs the diagnosis and prescription of adequate therapy for UC and UC. On the other hand, a number of systemic (extraintestinal) manifestations of UC are essentially complications of these diseases or a consequence of drug exposure. One of the most vulnerable in UC is the hepatobiliary system. More than 30% of patients with IBD have abnormal liver function tests, which prompts additional diagnostics.
References
Bambha K., Kim W.R., Talwalkar J. et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology. 2003; 125: 1364-1369
Bjo..rnsson E., Olsson R., Bergquist A., Lindgren S., Braden B., Chapman R.W., Boberg K.M., Angulo P. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008; 134: 975-980.
Broome U., Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis. 2006; 26: 31-41.
Buti M., García-Samaniego J., Prieto M. et al. [Consensus document of the Spanish Association for the Study of the Liver on the treatment of hepatitis B infection (2012)]. Gastroenterol Hepatol. 2012; 35: 512-528.
Chande N., Abdelgadir I., Gregor J. The safety and tolerability of methotrexate for treating patients with Crohn’s disease. J Clin Gastroenterol. 2011; 45: 599-601.
Chaparro M., Trapero-Marugan M., Guijarro M., Lopez C., Moreno-Otero R., Gisbert J.P. Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature. J Crohns Colitis. 2013; 7: e61-e65.
Chapman R., Fevery J., Kalloo A., Nagorney D.M., Boberg K.M., Shneider B., Gores G.J. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010; 51: 660-678.
Chevaux J.B., Bigard M.A., Bensenane M. et al. Inflammatory bowel disease and hepatitis B and C. Gastroenterol Clin Biol. 2009; 33: 1082-1093.
Culver E.L., Chapman R.W. Systematic review: management options for primary sclerosing cholangitis and its variant forms - IgG4-associated cholangitis and overlap with autoimmune hepatitis. Aliment Pharmacol Ther. 2011; 33: 1273-1291.
Czaja A.J. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci. 2013; 58: 326-343.
French J.B., Bonacini M., Ghabril M., Foureau D., Bonkovsky H.L. Hepatotoxicity Associated with the Use of Anti-TNF-α Agents. Drug Saf. 2016; Mar; 39 (3): 199-208.
Ghabril M., Bonkovsky H.L., Kum C. et al. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013; 11: 558-564.e3.
Gisbert J.P., Gonzalez-Lama Y., Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol. 2007; 102: 1518-1527.
Gisbert J.P., Luna M., Gonzalez-Lama Y., Pousa I.D., Velasco M., Moreno-Otero R., Mate J. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis. 2007; 13: 1106-1114.
Gizard E., Ford A.C., Bronowicki J.P., Peyrin-Biroulet L. Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2014; Jul; 40 (1): 3-15. Epub 2014, May 11.
Horn T.L., Reynolds J., de Villiers W., Pe~na L.R. Hepatitis C virus and inflammatory bowel disease. Dig Dis Sci. 2009 (25).
Janse M., Lamberts L.E., Franke L., Raychaudhuri S., Ellinghaus E., Muri Boberg K., Melum E., Folseraas T., Schrumpf E., Bergquist A. Three ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL and CARD9. Hepatology. 2011; 53: 1977-1985.
Joo M., Abreu-e-Lima P., Farraye F., Smith T., Swaroop P., Gardner L., Lauwers G.Y., Odze R.D. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol. 2009; 33: 854-862.
Loftus E.V., Kane S.V., Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2004; 19: 179-189.
Rojas-Feria M., CastroM., Suarez E. Hepatobiliary manifestations in inflammatory bowel disease: The gut, the drugs and the liver. World J Gastroenterol. 2013; Nov 14; 19 (42): 7327-7340.
McGowan C.E., Jones P., Long M.D., Barritt A.S. Changing shape of disease: nonalcoholic fatty liver disease in Crohn’s disease-a case series and review of the literature. Inflamm Bowel Dis. 2012; 18: 49-54.
Navaneethan U., Shen B. Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease.Inflamm Bowel Dis. 2010; 16: 1598-1619.
Navaneethan U., Venkatesh P.G., Lashner B.A., Shen B., Kiran R.P. The Impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis. Aliment Pharmacol Ther. 2012; Epub ahead of print.
Ojiro K. Naganuma M., Ebinuma H., Kunimoto H., Tada S., Ogata H., Iwao Y., Saito H., Hibi T. Reactivation of hepatitis B in a patient with Crohn’s disease treated using infliximab. J Gastroenterol. 2008; 43: 397-401.
Parente F., Pastore L., Bargiggia S., Cucino C., Greco S., Molteni M., Ardizzone S., Porro G.B., Sampietro G.M., Giorgi R. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study.Hepatology. 2007; 45: 1267-1274.
Saibeni S., Bollani S., Losco A., Michielan A., Sostegni R., Devani M., Lupinacci G., Pirola L., Cucino C., Meucci G. The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis. 2012; 44: 123-127.
Santos O.M., Mu~noz Ortiz E., Perez C., Restrepo J.C. [Autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome in adults: report of three cases]. Gastroenterol Hepatol. 2012; 35: 254-258.
Scherzer T.M., Staufer K., Novacek G., Steindl-Munda P., Schumacher S., Hofer H., Ferenci P., Vogelsang H. Efficacy and safety of antiviral therapy in patients with Crohn’s disease and chronic hepatitis C. Aliment Pharmacol Ther. 2008; 28: 742-748.
Shi J., Li Z., Zeng X., Lin Y., Xie W.F. Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res. 2009; 39: 865-873.
Silveira M.G. IgG4-associated cholangitis. Clin Liver Dis. 2013; 17: 255-268.
Sinagra E., Aragona E., Romano C., Maisano S., Orlando A., Virdone R., Tese L., Modesto I., Criscuoli V., Cottone M. The role of portal vein thrombosis in the clinical course of inflammatory bowel diseases: report on three cases and review of the literature. Gastroenterol Res Pract. 2012; 2012: 916428.
Sourianarayanane A., Garg G., Smith T.H., Butt M.I., McCullough A.J., Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis. 2013; 7: e279-e285.
Tada F., Abe M., Nunoi H. et al. Ulcerative colitis complicated with primary biliary cirrhosis // Intern med 2011; 50 (20): 2323-7. Epub 2011; Oct 15.
Titos Arcos J.C., Hallal H., Robles M., Andrade R.J. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis. Rev Esp Enferm Dig. 2012; 104: 282-284.
Uko V., Thangada S., Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol Res Pract. 2012; 2012: 642923.
Venkatesh P.G., Navaneethan U., Shen B. Hepatobiliary disorders and complications of inflammatory bowel disease. J Dig Dis. 2011; 12: 245-256.
Wester A.L., Vatn M.H., Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001; 7: 295-300.
